Haynes and Boone Adds Pharmaceutical Patent Practitioners Whitney Remily and John Bateman to Washington, D.C. Office

07/09/2015

The Washington, D.C. office of Haynes and Boone, LLP proudly announces the expansion of its Hatch-Waxman/ANDA Practice Group with the addition of Whitney Remily and John Bateman.

Both come to Haynes and Boone as partners from the Washington, D.C. office of Kenyon & Kenyon LLP, an intellectual property law firm.

Washington Partner Kyle Musgrove, who previously worked with Remily and Bateman at Kenyon, said the new acquisitions are talented lawyers who bring with them pharmaceutical experience that will help grow the firm’s already robust Hatch-Waxman practice.

“These additions will allow us to serve our clients even better,” Musgrove said.  “Whitney has a history of developing arguments that will hold up in litigation.  And, having had the opportunity to try cases with John in the past, I have seen his excellence in the courtroom. I am excited to have the opportunity to work with them again at Haynes and Boone.”

Said David Harper, leader of the firm’s Intellectual Property Litigation Section: “We are very fortunate that Whitney and John have agreed to lend their considerable talents to our growing generic pharmaceutical practice in Washington. Both of these professionals are very experienced dealing with the complex IP issues involved in bringing generic drugs to the marketplace. They will be an effective complement to Kyle and his existing team.”

Remily has more than 15 years of experience as a lawyer and registered patent agent. Her practice focuses on transactional work in the pharmaceutical field with a particular focus on rendering patent opinions (including the provision of detailed statements and notice letters) and conducting other forms of due diligence and landscape analyses. 

She has significant experience with various patent matters relating to filings of Abbreviated New Drug Applications by generic drug manufacturers. In this context, she has handled more than 500 opinion matters, including issues relating to FDA exclusivity, new chemical entities, importation of active ingredients, synthetic intermediates, polymorphs, approved and off-label indications, finished formulations/compositions and drug products.

Her practice also includes experience negotiating licenses, preparing and prosecuting patent applications (including patent term extensions) and counseling in litigation arising under the Hatch-Waxman Act.  And, in addition to pharmaceuticals, she has substantial experience in other technical areas including organic and inorganic chemistry, agrochemicals, cosmetics, diagnostics, polymers, food products, nutritional supplements, cigarettes, fine chemicals and medical devices.

Whitney previously worked at Merck & Co. as a synthetic organic chemist, where she was involved in the synthesis and development of pharmaceutical compounds.

Bateman has more than 20 years of experience litigating patent disputes, including serving as lead counsel at trial and on appeal.  His practice focuses on matters involving pharmaceuticals, medical devices, biotechnology and agrochemicals, with a special emphasis on representing generic companies in Hatch-Waxman cases.  He has worked with a wide variety of generic pharmaceutical clients, including companies based in the United States, India, Europe and Israel.

He has obtained favorable judgments for such clients after trial and on appeal, clearing the way for them to bring their products to market.  For example, Bateman and Musgrove represented an ANDA applicant at trial and on appeal in a case in which a patent covering a drug with sales of over $1 billion a year was found invalid and not infringed. 

He said he is looking forward to joining Haynes and Boone for several reasons. “Haynes and Boone has an outstanding pharmaceuticals practice, with great clients and skilled attorneys, and I feel lucky to be a part of it,” Bateman said. “And the firm’s recognized experience in inter partes review proceedings will be of tremendous benefit to the companies I work with, as such proceedings have become an integral component of litigation strategy in Hatch-Waxman matters.

“Plus, both Whitney and I were struck by the cooperative environment and genuine enthusiasm Haynes and Boone lawyers have for their firm.  That really stood out.”

Media Contacts

Nathan Koppel
Director of Media Relations
+1 512.867.8431
nathan.koppel@haynesboone.com
Linda Campbell
Communications Manager
+1 214.651.5362
linda.campbell@haynesboone.com

Related Industries

Email Disclaimer